• Data Bridge Market Research forecasts a 13.7% CAGR for the casino online gambling market to reach $144.74 billion in 2028
• Golden Matrix Group is demonstrating growth in both its B2B and B2C businesses, as it prepares to enter the Mexican markets
• GMGI revenue for the first nine months of fiscal 2022 was $26.46 million, up 237% from a year earlier, while the company notched its 16^th consecutive profitable quarter

For decades, there was little substantial innovation in the gambling industry and then along came the miracle of the internet and changed everything with the emergence on online gaming. Still, most traditional casino operators were slow to embrace the digital opportunity until the COVID-19 pandemic and subsequent lockdowns limited travel and shuttered their doors. That sparked a renaissance and provided a growth opportunity for companies like Golden Matrix Group (NASDAQ: GMGI), a provider of turnkey and white label gaming platforms, Esports technology and gaming content. Even with casinos opened again, the trend towards digital gaming is accelerating with no indications it will slow. Data Bridge Market Research this month forecast 13.7% compound annual growth for the casino online gambling market to reach $144.74 billion in 2028. Drivers abound, including increasingly realistic graphics where the lines between video games and online gaming are becoming blurred. Toss in the emergence of virtual and augmented reality to create the sensation of being in a casino and suddenly people have more money for gambling by saving on travel costs in favor of putting on a headset. Golden Matrix’s GM-AG System is the industry standard for gaming platforms, including leading graphics and over 10,000 games to give casino operators a copious number of options and management software to keep customers happy and loyal to their brand. As a rule, casinos can’t have enough online table games, which is right in GMGI’s wheelhouse. According to Gaming.com, cons of Caesars online casino, the company with the highest payout rate in the U.S., include a need for more online games. Golden Matrix is only scratching the surface of the bounds of its potential domain. Most of its business has historically been business-to-business with operators focused in Asia-Pacific. Last year, the company bought 80 percent of RKings Competitions Ltd., marking its entrance in the European markets, as well as business-to-consumer segment. The company is amid its next expansion move, which will bring RKings’ competitions to the Mexican markets. Through July, RKings has over 229,000 registered users. The growth is translating directly to quarterly results. In fact, the efficiently run company holds a streak of 16 consecutive profitable quarters. It is also flush with cash, having $15.87 million in cash and cash equivalents heading into its August-October quarter. During its third fiscal quarter ended July 31, 2022, Golden Matrix reported revenue of $9.1 million, up 180% from $3.25 million in the year prior quarter. Sales were nearly even between B2B and B2C segments at $4.26 million and $4.85 million, respectively. Net income for the quarter was $628,332, topping $484,613 in profits in Q3 fiscal 2021. For the first 9 months of the fiscal year, the company logged revenue of $26.46 million, up 237% from $7.84 million a year earlier. Net income was $1.56 million compared to $664,757 last year. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content offerings to support the needs of our millions of participants,” said Golden Matrix CEO Anthony Brian Goodman in a news release on the recent quarter. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• California’s Consumer Privacy Act, Privacy Rights Act, and Europe’s General Data Protection Regulation represent a changing data market
• Reklaim is a leader in compliant data with a comprehensive platform that allows consumers to re-take control of their data and be compensated should they decide, it can be bought and sold
• Reklaim’s revenue jumped 277% year-over-year to $645,008 in Q2 as the company grows organically and explores accretive M&A opportunities

In years gone by, not long ago, companies were quietly hoarding as much data as possible from consumers, then promptly selling it for the maximum amount with little to no concern if the consumer liked it or not. Thankfully, a paradigm shift is happening with new privacy laws in North America, namely the California Consumer Privacy Act (“CCPA”) and the California Privacy Rights Act (“CPRA”), and Europe with its General Data Protection Regulation (“GDPR”), paving the way for litigation against data companies if they don’t comply. That has created an opportunity for companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) to burst on the scene with an innovative privacy-compliant identity ecosystem. Unable to secretly swipe consumer data, many companies in the data space find themselves in unfamiliar territory with little infrastructure to communicate with consumers. There is no skirting the laws, which undergirds why Reklaim believes many of these firms coping with the changing regulatory climate “will suffer significant revenue declines, and those without a compliance partner will likely cease to exist.” The implications are tremendous. Consider that Facebook parent Meta said it expects a $10 billion write-down on revenue in 2022 because of changes Apple made to halt user tracking on external applications. To be clear, Apple’s App Tracking Transparency feature doesn’t stop all data collection, but it did upend the $200 billion US data market and caused data users to scramble to rethink strategies, just like they have to do with the shifting regulatory landscape. For enterprise software juggernaut Oracle, a massive class-action lawsuit has been filed alleging privacy violations for collecting, profiling, and selling data on five billion users worldwide. Further evidence of the trend is shown in the Federal Trade Commission filing a lawsuit against data broker Kochava Inc. for selling geolocation data from mobile devices that identified people at places of worship, addiction clinics, domestic violence shelters, and other highly sensitive locations. Reklaim is an eye-opener, allowing consumers to log in to their platform and confirm their identity, unlocking data collected on them, bought, and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms, and data companies. The company also has a subscription service for consumers that shrinks the amount of data leaking from their devices and delivers alerts on password and third-party data breaches. As described by Sophic Capital, the supply of data is dramatically shrinking owing to new laws and actions of Apple and Google, which are planning on banning third-party cookies in Chrome, which will remove 65% of tracking from 1.8 billion websites on the open web today; further complicating companies trying to monetize data. Compliant data is not going to be the gold standard; it will be the only standard for brands to walk confidently within the parameters of the law. Reklaim also provides the ability to scale compliant targeting marketing initiatives with its database of compliant data for 350+ million profiles in the U.S. alone. With the CCPA and CPRA going into effect shortly, business is picking up at Reklaim. During the second quarter, total revenue increased 277% to $645,008 from Q2 0221 and 65% from the first quarter of 2022. Recurring revenue accounted for 85% of the total revenue in Q2 2022 and was up 87% during the year’s first half compared to a year earlier. According to Reklaim CEO Neil Sweeney, the company is focused on driving costs out of operations and exploring strategic acquisitions that can be immediately accretive to bolster the top and bottom line at a time when the compliant data market is about to go through a growth spurt. Realizing a “strike when the iron is hot” opportunity, Reklaim intends to increase its sales force to meet demand and foster further organic growth. The addressable market in the U.S. is transformational on its own. However, this is global. Market research firm Gartner forecast in May called for a regulatory evolution that will result in 75% of the worldwide population having its personal data covered under privacy regulations by the end of 2024. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Flora Growth is a global cannabis cultivator, product builder, and supplier, experiencing continued growth thanks to strategic acquisitions and an expanding supply chain for marketing its brands in various countries
• Flora announced its most recent acquisition in September — a deal to acquire the assets of the No Cap Hemp Co. brand in exchange for payment of 10 percent of the No Cap brand revenues up to a maximum of $2 million
• The deal grants Flora an immediate revenue stream free of closing cost considerations
• Flora has seen revenues skyrocket over the past year, with a 604 percent YOY increase in the H1 reporting period

Global cannabis cultivator, product manufacturer and distributor Flora Growth (NASDAQ: FLGC) is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. The company recently reported a 604 percent increase YOY in its H1 revenues to about $15 million, which was also a 117 percent increase over the previous half-year financial report, and is anticipating new momentum from the recent acquisition of the No Cap Hemp Co. brand by Flora’s wholly owned subsidiary Just Brands LLC. The No Cap acquisition is expected to add some 75 SKUs to Flora’s product portfolio plus the “No Cap” and “Moonblunt” trademarks, according to a Sept. 7 company news release. “This transaction will allow Flora to immediately benefit from a profitable, cash flow positive and growing business,” Flora Growth Chairman and CEO Luis Merchan stated (https://ibn.fm/MAdTI). “We look forward to increasing our product offering through this transaction while broadening our sales team in the process.” Flora is headquartered in Canada where cannabis legalization has been pioneered, but the heart of the company’s operation is in northern Colombia, where its Cosechemos cultivation, extraction, and isolation facility, draws on an experienced workforce in the country’s fertile greenbelt to produce its brands. Colombia is itself undergoing a cannabis transformation as it enacts progressive drug policy changes, establishing a regulatory framework to govern cannabis cultivation and exports. In August, Flora announced a distribution agreement with the Misak indigenous tribe’s pharmaceutical arm, which became the first native community business to receive a license from the national Ministry of Justice for legal cannabis production for medicinal and scientific use two years ago (https://ibn.fm/eC25I). The deal allows Flora to take advantage of the tribe’s “unique regulatory positioning” to rapidly advance the fulfillment of cannabis exports. Merchan anticipates that the acquisition of No Cap’s brands will ultimately position Flora as the leader in the alternative cannabinoid market segment and that No Cap’s infusion technology will boost Flora Labs’ manufacturing capabilities. “We continue to prudently manage our overhead and working capital as we expect to improve profitability going forward. With all three of our core pillars generating revenue in the second half of 2022 … we believe we have a path to profitability that few global cannabis companies can achieve in this difficult environment,” Merchan stated in August (https://ibn.fm/pU1hs). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• SGMD inks MSA with California cannabis micro license holder
• Agreement “lays a foundation for a significantly expanded manufacturing and distribution infrastructure,” says CEO
• Key partnerships are essential pieces of Sugarmade’s focus on California cannabis space

With the recent signing of a management services agreement (“MSA”) (https://ibn.fm/2KYof), Sugarmade (OTC: SGMD) is making key progress toward the goal of strengthening its position in the California cannabis space. SGMD signed the MSA through its subsidiary, SugarRush, which entered into the agreement with Canndis Inc., a California cannabis micro license holder. Canndis holds a license that covers delivery, manufacturing, distribution and cultivation rights, and the agreement will enable Sugarmade to expand its manufacturing and distribution footprint. “This deal will provide us with a new income stream as we apply our expertise and experience to mobilize Canndis’ assets and market positioning,” said Sugarmade CEO Jimmy Chan. “But it also has substantial strategic value because it lays a foundation for a significantly expanded manufacturing and distribution infrastructure under our control when we harvest our first crop.” Sugarmade is anticipating harvesting that crop in the coming weeks, an accomplishment made possible through the company’s acquisition of a minority stake in RMI Ventures (d/b/a Jerusalem Grade Farm) (https://ibn.fm/33N2u); the property is licensed for 43,560 square feet of outdoor canopy area and is currently growing at full capacity this season. Sugarmade and RMI Ventures signed an LOI earlier this year. These strategic agreements are essential pieces of Sugarmade’s focus on growing its presence in the cannabis space. The MSA calls for Sugarmade to assume management responsibilities and operational control over manufacturing and distribution of cultivated cannabis produced Jerusalem Grade Farm. The agreement also expands Sugarmade’s manufacturing and distribution footprint and will provide for the establishment of a new strategically located manufacturing and distribution hub near Palm Springs, California, as Sugarmade brings that harvest to market. Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s brand portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, J Grade Farm, Lemon Glow and Budcars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Todd Michaels, Correlate’s President and CEO, shared some insights into the company’s operations, how it came to be, and its plan for the future. He also shared his journey into the clean energy space
• He emphasized that the company is committed to helping corporations and companies to generate clean energy on-site and set up better technology that guarantees an instant increase in NOI
• Todd mentioned that Correlate looks to make it increasingly simple for people to find the company and take advantage of its offerings. This, he noted, would be facilitated by the company’s ever-growing team of experts, as well as its technology
• Correlate has two or three more acquisitions in the queue, which will be integral in expanding the company’s overall footprint and capabilities. These acquisitions will also aid in the company’s efforts to create new product packaging and delivery while also exploring other markets, mainly Hawaii

Correlate Infrastructure Partners (OTCQB: CIPI), a portfolio-scale real estate platform focused on eliminating barriers for large-scale property owners looking to improve their Net Operating Income (“NOI”), has achieved tremendous growth over the past couple of years. This growth has been primarily attributed to the company’s understanding of the renewable energy market and the competence of its leadership, starting with Todd Michaels, Correlate’s President and Chief Executive Officer (“CEO”). While appearing in an interview published on the company’s website, Todd shared incredible insights into the company’s operations, how it came to be, and its plan for the future. In addition, he shared his journey into the clean energy space, along with what it took for him to grow the company into what it is today. “From hiking and camping to fishing, I’ve always enjoyed the outdoors, and my love of nature led me to getting into sustainability at an early age,” Todd noted (https://ibn.fm/ky4SM). With a background in emerging technology in communication and seven years of experience in Silicon Valley, Todd recognized an opportunity within the clean energy space and opted to jump in. Today, he notes, Correlate is committed to solving two main problems that corporations and companies, including the government, face regarding clean energy generation- how to generate clean energy on-site and how to set up better technology, including new infrastructure that runs off of renewable energy sources. To this end, the company has embarked on an ambitious project to improve buildings upfront while maintaining them over time, ultimately simplifying energy upgrades and making renewable energy solutions more accessible. Todd lauded his team, describing them as “a group of serial entrepreneurs in the clean energy space.” He also mentioned that the company looks for people who have forward-thinking mentalities and the ability to adapt, mainly since the industry Correlate is in changes and evolves quickly. While asked to share what sets Correlate apart, Todd reiterated that the company has the discipline of a large publicly traded company and the innovative mindset of a start-up. He further noted that while the company has made significant strides so far, it is still working towards being the first profitable, rapidly-growing, publicly-traded clean energy company with over a billion dollars in market capitalization, all in under two years. “[I am most excited about] building a profitable, savvy, and nimble billion dollar business that can also innovate- and doing it quickly. I want the best people to work here because we are so different and progressive, yet we’re also stable and admired,” Todd stated. Going forward, Correlate looks to make it increasingly simple for people to find the company and take advantage of its offerings that instantly enable them to increase NOI and meet their sustainability goals. This, according to Todd, will be achieved through the company’s ever-growing team of experts and its technologies. He also noted that the company has two or three more acquisitions in the queue geared towards expanding the company’s overall footprint and capabilities. The acquisitions will complement Correlate’s list of subsidiaries comprising Correlate and Solar Site Design. They will, similarly, aid in the company’s creation of new product packaging and delivery while exploring other markets, mainly Hawaii. Throughout the interview, Todd noted how pleased he was about the company’s current trajectory and expressed his optimism for the company’s future. Most notably, he cited the approval of the $369 billion Inflation Reduction Act, which has so far transformed his team from being investors freaked out about the solar market’s future to “seeing a clear ten years of stability.” To read the full interview, visit https://ibn.fm/ky4SM For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

Date: October 7-9, 2022 The first of its kind Cannabis event ‘The High Lifestyle Show’ is finally being held in Massachusetts, on October 7-9, 2022 at the Regency Hotel (Boxborough, MA). The event is organized by NECANN, the leading cannabis event organizer on the East Coast. Being held in a sprawling plush resort hotel, the event will witness a huge gathering of brands, dispensaries, distributors, growers, performers, and consumers, along with exhibitors, vendors, experts, and celebrities, all interacting in a positive socializing and networking environment. While other Canna events revolve around cannabis manufacturing and medication, this NECANN event is a complete lifestyle event that discusses the novel cannabis products and innovative ideas, cultivation and manufacturing techniques, trade, recreation, prospects and health aspects, all in a conducive setting amidst several artists performing to entertain the audience. The NECANN events attract a huge number of hemp, MMJ, and cannabis industry professionals in the Northeast. These events are the home base for the New England cannabis industry. NECANN’s ‘The High Lifestyle Show’ is a great platform for newbies and budding entrepreneurs to get discovered by capital investors. It offers robust networking and business opportunities for cannabis growers, consumers and industries across the region. With medicinal and recreational marijuana legal in Massachusetts, the participants at the lifestyle event are expected to grow phenomenally. The event is attended by industry thinkers and cannabis leaders who share their views, insights, and ideas, and discuss the future trends of this evolving industry. the latest laws and regulations in the cannabis market are also discussed at this unique show. Witness highly effective B2B and B2C networking, where vendors, traders, enthusiasts and industry veterans, discuss and exchange interesting ideas and education. Adults over 21 in Massachusetts now have the freedom to buy cannabis products from their favorite brands and retail outlets. Exhibitors will set up booths from where they will pitch their products and services. (No THC products will be on sale at the event campus). The networking amongst attendees and industry veterans will take place in a fun and interactive setting designed to encourage a tremendous exchange of critical professional knowledge related to the products, regulations, and trends, of the fast developing cannabis industry. To know more, please visit https://ibn.fm/IvBQJ.

• Renewable energy demand has seen a further increase on the back of rising utility costs
• Orlando’s Utility Commission recently introduced its third utility price hike of the year and have warned of another potential increase come January 2023
• Meanwhile, solar energy prices have now fallen below those of conventional, fossil-fuel generated energy
• GeoSolar Technologies proprietary home solution provides homeowners with a mix of lower utility costs and energy independence

Speaking at the United Nation’s Climate Change Conference (COP26) last year, Richa Sharma, leader of the Indian delegation stated “The meagre carbon budget is first and foremost the right and entitlement of developing countries” (https://ibn.fm/UMDqX). At the time, Sharma was arguing that developing nations should be given first right towards using carbon-intensive fossil fuels to drive their respective economies in the face of global carbon emission quotas; in fact and only months prior to the meeting, the International Energy Agency had forecast that India’s installed capacity of coal would grow by 80 percent between 2018 and 2040 (https://ibn.fm/GRRx7). A year later, the agency saw fit to revise down that figure to just 10 percent. Renewable energy sources like wind and solar have seen their cost structures decline dramatically in recent years, arriving at cost parity with fossil-fuel powered energy sources in several global markets. The decline in renewable energy costs coupled with the exponential rise in fossil fuel prices have led to a dramatic increase in renewable energy demand, a phenomenon which the likes of climate technology company GeoSolar Technologies (“GST”), are seeking to capitalize on. Despite their higher upfront costs – it costs an average of $18,000 to install a 6kW grid-tied solar system, solar energy home systems have long posed an attractive investment proposition for homeowners. Solar panels have a usable lifespan of 25 years on longer; homeowners who install solar panels tend to break even within six to ten years due to utility bill savings (https://ibn.fm/dJ6Pc) providing for an attractive return on investment. Whilst the investment case for solar panels has been generally well-understood, recent, volatile moves in hydrocarbon prices – US natural gas prices spiked to a 14 year high in August – have served as a further incentive for homeowners seeking to shift towards renewable energy sources. Florida’s Orlando Utilities Commission (“OUC”) lately provided a stark illustration of the ongoing paradigm shift within energy prices. The municipal utility recently approved a rate increase for most of its residential customers, leading utility bills to rise by anywhere between $5 to $15 a month. Having already been obliged to raise rates thrice this year, the OUC did not rule out a further hike come January. However, and unlike electricity generated from fossil fuels, solar energy prices have remained unchanged. OUC’s Chief Financial Officer, Mindy Brenay elaborated on the change in electricity pricing as well as the relative attraction of solar power in the current environment. “Community solar has [historically been priced at a premium over traditional fuel pricing, and that has been the case since we have implemented solar. The price of solar has continued to come down, but it has traditionally been higher than our standard fuel price Now with this unusual spike we’re seeing in fuel, we want to do everything we can to lower the fuel costs. So, these solar costs, which are now actually lower than our traditional, are being blended in to give all customers the opportunity to share in those lower costs from solar,” (https://ibn.fm/eD9Nk). GeoSolar Technologies have sought to build upon the growing move towards solar energy adoption thorough a multi-pronged approach which looks to electrify homes using green energy sources. From solar panels on roofs through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, GeoSolar’s proprietary SmartGreen™ Home solution has been designed to dramatically increase the energy efficiency of a conventional household. Moreover, the technology voids the need for households to depend on conventional utilities or pay utility bills. In fact, a study carried out by the company found that a traditional utility-powered home would possess a carbon footprint of upwards of 8 tons of CO2/year whilst paying annual utility bills of $2,700; in contrast, a GeoSolar-powered home would result in a negligible carbon footprint whilst disbursing less than $100 per annum in utility bills (https://ibn.fm/AGcTL). Providing homeowners with a heady combination of lower utility costs and ultimate energy independence, GeoSolar Technologies and its proprietary energy solution find themselves ideally situated to satisfy one of the fastest growing sources of consumer demand in the United States, today. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM)
• Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in greater bioavailability; pre-clinical and human studies have demonstrated that DehydraTECH-CBD enables absorption increases of between 100% and 500% The studies have also shown that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure among hypertension patients
• Lexaria, which believes there is a significant unmet demand for cost-effective hypertensive treatments with few or no side effects, is working toward commercializing DehydraTECH-CBD to satisfy this demand

Currently, roughly 20% of people diagnosed with hypertension take medication, with the remaining majority noting that the medications’ side effects substantially outweigh the benefits. This has often constrained the fight against hypertension, the most common cardiovascular disease worldwide, which affects more than one billion people and is associated with long-term morbidities such as heart disease, stroke, and even death. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, believes the hesitance or refusal to take medication presents a significant unmet demand for more tolerable, cost-effective anti-hypertensive treatments and has been working to bring such treatments to the masses. Specifically, the company is developing a new potential treatment with few or no side effects to address a majority of hypertensive patients’ concerns about taking hypertension medication. The company’s drug candidate, DehydraTECH(TM)-processed CBD, has been the subject of animal and human studies, which have yielded “extremely promising early results,” according to Prof. Philip Ainslie, PhD., Lead Investigator in Lexaria’s human hypertension studies, who was recently interviewed by PCG Digital (https://ibn.fm/gKxMY). These results are thanks, in part, to the improved performance offered by the company’s patented DehydraTECH drug delivery technology. The technology, Lexaria’s studies have shown, increases the intestinal bioabsorption of bioactive compounds by as much as 27 times. This results in greater bioavailability of these therapeutics at lower doses. Nowhere else is this as apparent as in the case of CBD. CBD or cannabidiol, Prof. Ainslie explained, “is a complex fat-soluble molecule and is known to have poor absorption characteristics. Typically, only about 6% of what is orally ingested enters the bloodstream. Through our pre-clinical and human studies, we have shown that DehydraTECH technology enables absorption increases of between 100% and 500%.” Additional results from the company’s 2021 studies – HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3 – have demonstrated that DehydraTECH-CBD caused a rapid and sustained reduction in blood pressure among hypertensive volunteers. “The improvements in blood pressure results were particularly remarkable given the fact that many existing drugs used to treat hypertension require several weeks of treatments and/or combination dosing before they produce comparable reductions in blood pressure,” underlined Prof. Ainslie. Just recently, Lexaria completed its most comprehensive human hypertension study, HYPER-21-4, which enabled them to gather critical data monitoring the safety and efficacy of the DehydraTECH-CBD formulation over a prolonged period. The study, Prof. Ainslie noted, will allow the company to evaluate the formulation’s potential for longer-term health benefits. The completed studies are, however, just the beginning – Lexaria plans to undertake clinical trials with the FDA that seek to demonstrate the safety and tolerability profile relative to conventional anti-hypertensive medications. These trials will also aim to avoid serious adverse events at clinically efficacious doses. According to the Lead Investigator, establishing safety is extremely important because, though often well-tolerated, CBD can potentially cause liver toxicity, particularly when given in the high therapeutic doses required for conditions such as epilepsy or hypertension. As a baseline, Epidiolex, the only FDA-approved CBD drug, has an approved dose of 10mg per kilogram of body weight, given twice daily. Lexaria, however, believes its DehydraTECH technology has the potential to reduce the prescribed doses because of its ability to enhance CBD’s bioavailability. “There could be significant benefits in allowing its dosing to be reduced while maintaining therapeutic delivery levels, and we have already been investigating a range of doses lower than those already approved by FDA for Epidiolex, for example,” Prof. Ainslie emphasized. The completed and planned research is part of a greater goal: commercialization. To that end, Lexaria has engaged the FDA resulting in confirmation that the agency supported the company’s proposal to pursue the abbreviated 505(b)(2) New Drug Application (“NDA”) (https://ibn.fm/tZz5Y). The abbreviated pathway enables a faster route to commercial approval than the traditional pathway. Presently, and following the confirmation, the company is working on preparatory work that will facilitate the filing of an Investigational New Drug (“IND”) application and is on track to file by year’s end or early 2023. Thereafter, and upon approval of the application, Lexaria expects to commence its proposed US-based Phase 1b clinical trial involving about 100 hypertension patients. As part of the study, the participants will receive a dose of DehydraTECH-CBD to evaluate the safety and efficacy of the formulation as well as 24-hour ambulatory blood pressure. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• iGaming market expected to double from $173 billion to over $340 billion by 2027
• GMGI recently posted record-breaking Q3 revenue results, 16 non-stop profitable quarters
• GMGI’s industry-standard GM-Ag System provides access to 10,000+ games, simplifies payment options, leverages data analytics to provide total 360-degree performance visibility

The iGaming market continues its rapid pace of growth with expectations it will double from $173 billion to over $340 billion by 2027 (https://ibn.fm/8JO3m).  Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms and systems, continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly revenues (https://ibn.fm/AATls). “Our ability to generate increasing revenues with quarter-after-quarter of profitability attests to the strengths of our B2B and B2C platforms,” said GMGI CEO Anthony Brian Goodman. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content offerings to support the needs of our millions of participants.” iGaming is a diverse industry comprising numerous forms of online gambling, including regular online casinos, poker rooms, e-sports betting, crypto casinos, and binary trading. Factors contributing to industry growth are linked to the increased availability of smartphones, laptops, and virtual reality headsets. In addition, Covid-19 pandemic restrictions catalyzed industry expansion by driving people to online activities when government mandates forced casinos and other entertainment venues to close. Casino aggregator platforms additionally fuelled industry growth by reducing barriers to entry and easily connecting operators to suppliers, payment systems, and gaming content. GMGI’s next generation GM-Ag System – the industry standard – provides access to 10,000+ games while simplifying payment options via seamless integrations with third-party platforms and digital wallets. GM-Ag additionally supports all major currencies, offers multiple language options, and can be accessed by any major operating system on any device with an internet connection. The platform also features AI-based tools that help operators derive maximum revenue from each player, and data analytics that enable complete 360-degree performance visibility. “The GMX-Ag (aggregate) platform, which provides numerous features to benefit both operators and their players, continues to gain traction, even outside our traditional markets,” said Goodman. “Additionally, on the B2B side, we provide our operators with the marketing tools they need to strengthen their customer acquisition and retention.” Based in Las Vegas, Golden Matrix is an established gaming technology company that currently supports over 645 operators and 6.8 million players in its B2B business, and over 229,000 players in its RKings B2C segment. With a proprietary portfolio of highly modular, configurable, and scalable AI-powered gaming platforms, GMGI is strongly positioned to lead the hyper-growth iGaming industry. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

Life science and health care professionals, as well as consumers, are invited to attend the 6th Digital Strategy & Innovation for Medical Affairs Summit on November 2-3, 2022. Participating pharma and medical companies can learn how to streamline their medical department affairs using innovative digital transformation policies that experts share and discuss at the DGE event. The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. The 6th Digital Strategy Summit is the largest event devoted to the medical industry that is being streamed live on an established interactive platform. The event will witness life science experts of global acclaim sharing a common platform at the symposium. They will offer valuable advice on successfully employing digital strategies to stay relevant. The evolving landscape of the medical arena owing to COVID-19 makes it essential to design futuristic digital marketing strategies. Attendees can benefit from an all-access ticket to three DGE events. Register for DGE’s 3rd Next-Gen MSL Excellence or the 2nd Investigator-Initiated Trials Summit, and attend sessions from any of the events. The featured discussions at the Summit:

• Harness the potential of novel technologies for better growth and development
• Improvise the regulations for accommodating digital health practices
• Learn about new avenues to engage with stakeholders
• Design-customer centric strategies
• Engage audiences effectively using media and messaging
• Best practices for cross-functional collaboration among teams
• Robust social media strategies for expanding outreach
• Learn new ways to shape omnichannel outreach

As patients get access to multiple channels of medical and scientific information, every medical affairs team has to stay updated with the new technologies and evolving marketing strategies. Biotech, pharma, and life science organizations, must all evolve and look for new ways to engage the audience. Experts will speak about the importance of Real World Evidence and how it can be a game-changer in benefitting the organization as a whole. Multichannel digital strategies by small and mid-size companies can play a pivotal role in disease state education and clinical trial awareness for stakeholders, especially in the case of rare diseases. Learn strategies and tips for digital innovation to ensure that data reaches the stakeholders as and when they need it. Also, discover new publication amplification strategies to increase visibility and engagement. To learn more, please visit https://ibn.fm/2MrTz.